From the PR, for the books here on SI: Ivan Lieberburg, Ph.D., M.D., Elan's Chief Scientific and Medical Officer stated that, ``Elan's partnering strategy gives us the opportunity to leverage very important technology with leaders in their respective fields. I am particularly excited about entering into this important collaboration with Curis. Curis is clearly the world leader in Hedgehog technology, and there is now growing evidence that Hedgehog agonists could have broad reaching applications in a variety of neurological disorders that are extremely important to Elan,
including Parkinson's disease, neuropathy, pain, multiple sclerosis and Alzheimer's disease.''
``The business venture with Elan demonstrates the value of Curis' strong position in the exploitation of
developmental pathways in tissue regeneration,'' said Dr. Doros Platika, M.D., President and Chief
Executive Officer of Curis. ``We have identified growth factors and small molecules that have broad
applications in many disease areas. This joint venture structure allows Curis to secure the resources for the
development of its extensive pipeline while at the same time allowing it to retain a significant portion of the
value creation.''
Jim |
